Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells

Molecular Pharmacology

Volumn 72, Issue 1, 2007, Pages 162-172

  Merighi, Stefania ^a   Benini, Annalisa ^a   Mirandola, Prisco ^b   Gessi, Stefania ^a   Varani, Katia ^a   Leung, Edward ^c   Maclennan, Stephen ^c   Baraldi, Pier Giovanni ^a   Borea, Pier Andrea ^a,d,e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c King Pharmaceuticals   (United States)

^d Interdisciplinary Center for the Study of Inflammation   (Italy)

^e Section of Pharmacology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR A3; ADENOSINE RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADENOSINE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ADENOSINE A3;

EID: 34347206794     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.031849     Document Type: Article

References (41)

1. Adams JM and Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326.
2. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, and del Peso L (2001) Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 276:22368-22374.
3. Andresen BT, Gillespie DG, Mi Z, Dubey RK, and Jackson EK (1999) Role of adenosine A1 receptors in modulating extracellular adenosine levels. J Pharmacol Exp Ther 291:76-80.
4. Blay J, White TD, and Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602-2605.
5. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, and Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms. Science 286:1358-1362.
6. Cardone MH (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321.
7. Chamberlain MC and Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13:2066-2071.
8. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, et al. (2003) BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424:952-956.
9. Danial NN and Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-219.
10. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
11. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, and Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687-689.
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
13. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, and Dive C (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24:2875-2889.
14. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 59:76-82.
15. Glantz MJ, Chamberlain MC, Chang SM, Prados MD, and Cole BF (1999) The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 9:27-33.
16. Guensberg P, Wacheck V, Lucas T, Monia B, Pehamberger H, Eichler HG, and Jansen B (2002) Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 48:189-195.
17. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
18. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, and Murata Y (2000) Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60:5988-5994.
19. Holland EC (2001) Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2:120-129.
20. Hu L (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092.
21. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ, Andrews D, Knudson CM, and Yang E (2003) Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J 22:5459-5470.
22. Kemper EM, Boogerd W, Thuis I, Beijnen JH, and van Tellingen O (2004) Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 30:415-423.
23. Mabuchi S (2002) Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277:33490-33500.
24. Maslyar D, Aoki M, and Vogt PK (2001) The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3. Oncogene 20:5087-5092.
25. 3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 7:894-903.
26. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, and Borea PA (2005b) A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280:19516-19526.
27. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, and Borea PA (2006) Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 72:19-31.
28. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, and Borea PA (2002) Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119:923-933.
29. Merighi S, Mirandola P, Varani K, Gessi S, Capitani S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003a) Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: paclitaxel and vindesine. Biochem Pharmacol 66:739-748.
30. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003b) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31-48.
31. Piret JP, Cosse JP, Ninane N, Raes M, and Michiels C (2006) Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res 312:2908-2920.
32. Rosenthal MA, Gruber ML, Glass J, Nirenberg A, Finlay J, Hochster H, and Muggia FM (2000) Phase II study of combination paclitaxel and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. J Neurooncol 47:59-63.
33. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, and Paniagua R (2001) Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw 12:654-663.
34. Ryzhov S, McCaleb JL, Goldstein AE, Biaggioni I, and Feoktistov I (2007) Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. J Pharmacol Exp Ther 320:565-572.
35. 3 receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 62:1137-1146.
36. Schulte G and Fredholm BB (2003) Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15:813-827.
37. Seo SY, Chen YB, Ivanovska I, Ranger AM, Hong SJ, Dawson VL, Korsmeyer SJ, Bellows DS, Fannjiang Y, and Hardwick JM (2004) BAD is a pro-survival factor prior to activation of its pro-apoptotic function. J Biol Chem 279:42240-42249.
38. Shannon AM, Bouchier-Hayes DJ, Condron CM, and Toomey D (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297-307.
39. Suzuki A, Kusakai G, Shimojo Y, Chen J, Ogura T, Kobayashi M, and Esumi H (2005) Involvement of transforming growth factor-β1 signaling in hypoxia-induced tolerance to glucose starvation. J Biol Chem 280:31557-31563.
40. Vaupel P, Thews O, and Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243-259.
41. Yamaguchi H and Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20:7779-7786.